Let Us Solve Your Solubility/Bioavailability Issues.
LLS Health Feasibility Programs
The CDMO Division of LLS Health regularly receives inquiries on overcoming poor solubility/bioavailability, developing long-acting dosage forms, and increasing the lifespan of implantable products. Our passion for overcoming complex formulation challenges helps us find the best solution to achieve your goals.
Why LLS Health?
We offer feasibility programs designed to accelerate product development in these focus areas. These programs utilize trusted technologies to provide early-stage support in relatively quick, cost-effective packages. If a feasibility program proves successful, LLS Health is positioned to provide ongoing optimization, scale-up, and manufacturing for each product type. Learn more about our feasibility offerings at the links below.
Nanomilling is an efficient, reproducible, and scalable approach for improving the rate of dissolution and bioavailability of BCS Class II and IV compounds. If you have an insoluble API, contact us to learn how nanomilling can help solve your formulation challenges, and let us take your product from concept to commercial.
Long-acting depot injections are high-value products that offer an appealing route to improved patient compliance and reduced administration frequency. If you are interested in developing a microparticle depot injection, then partner with LLS Health, a CDMO with extensive microparticle and microsphere development expertise.
LLS Health is addressing the growing need for implantable materials with our dexamethasone-loaded polymer offering. By combining trusted, biocompatible polymers (silicone, TPU, EVA, PLGA, and others) with a safe, effective anti-inflammatory agent (dexamethasone), we can supply ready-made material that is ideal for prototyping and product development efforts.